产品说明书

Piroxicam

Print
Chemical Structure| 36322-90-4 同义名 : CP-16171;NSC 666076
CAS号 : 36322-90-4
货号 : A265438
分子式 : C15H13N3O4S
纯度 : 98%
分子量 : 331.346
MDL号 : MFCD00057317
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 50 mg/mL(150.9 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • COX
描述 Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively[3]. Piroxicam (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration[4]. Piroxicam (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells. In vitro combination of carboplatin and piroxicam produced a more potent antiproliferative effect when compared to single drugs[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03038321 Non-Muscle-invasive Bladder Ca... 展开 >>ncer (NMIBC) Bacillus Calmette-Guerin (BCG) Cystitis Intra-vesical Instillation 收起 << Phase 4 Active, not recruiting December 2019 Egypt ... 展开 >> Urology and Nephrology Center Mansoura, Aldakahlia, Egypt, 35516 收起 <<
NCT02457325 Impacted Third Molar Tooth ... 展开 >> Adverse Reaction to Other Local Anesthetics 收起 << Phase 4 Completed - -
NCT02160236 Postoperative Pain Phase 4 Unknown February 2015 Turkey ... 展开 >> Erciyes Universty Hospital Recruiting Kayseri, Turkey, 38039 Contact: nazife küçük, resident    +905072317446    nzfkucuk@hotmail.com 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.02mL

0.60mL

0.30mL

15.09mL

3.02mL

1.51mL

30.18mL

6.04mL

3.02mL
参考文献

[1]Vartiainen N, Huang CY, et al. Piroxicam and NS-398 rescue neurones from hypoxia/reoxygenation damage by a mechanism independent of cyclo-oxygenase inhibition. J Neurochem. 2001 Jan;76(2):480-9.

[2]Rigas B, Tsioulias GJ, et al. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology. 1994 Oct;83(2):319-23.

[3]Kato M, Nishida S, Kitasato H, Sakata N, Kawai S. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001;53(12):1679-1685

[4]Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002;62(2):356-358

[5]Silva J, Arantes-Rodrigues R, Pinto-Leite R, et al. Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines. Anticancer Res. 2017;37(4):1737-1745